<DOC>
	<DOC>NCT02586025</DOC>
	<brief_summary>This is an Asia-Pacific regional, randomized, double-blind, Phase III, multicenter trial designed to evaluate treatment with trastuzumab plus pertuzumab plus docetaxel compared with trastuzumab plus placebo plus docetaxel in chemotherapy-na√Øve patients with early-stage or locally advanced HER2-positive breast cancer. The anticipated treatment duration is approximately 17 months.</brief_summary>
	<brief_title>A Randomized, Double-Blind, Placebo-Controlled Study in Patients With Early-Stage or Locally Advanced HER2-positive Breast Cancer to Evaluate Treatment With Trastuzumab + Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirmed invasive breast carcinoma with a primary tumor size of &gt; 2 cm by standard local assessment technique Stage at presentation: earlystage (T23, N01, M0) or locally advanced (T23, N2 or N3, M0; T4, any N, M0) HER2positive breast cancer confirmed by a Sponsordesignated central laboratory and defined as 3+ score by immunohistochemistry (IHC) in &gt; 10% of immunoreactive cells or HER2 gene amplification (ratio of HER2 gene signals to centromere 17 signals &gt;/= 2.0) by in situ hybridization (ISH) A tumor sample consisting of a tumor block or eight unstained, freshly cut slides must be available for central laboratory HER2 testing by IHC and ISH Known hormone receptor status (ER and PgR) Eastern Cooperative Oncology Group (ECOG) Performance Status &lt;/= 1 Baseline left ventricular ejection fraction (LVEF) &gt;/= 55% measured by echocardiography (ECHO) (preferred) or multiple gated acquisition (MUGA) scan Negative serum pregnancy test Stage IV metastatic breast cancer Inflammatory breast cancer Previous anticancer therapy or radiotherapy for any malignancy History of other malignancy, except for carcinoma in situ of the cervix or squamous or basal cell carcinoma Concurrent anticancer treatment in another investigational trial, including hormone therapy, bisphosphonate therapy, or immunotherapy Major surgical procedure unrelated to breast cancer within 4 weeks prior to randomization or from which the patient has not fully recovered Serious cardiac illness or medical condition Other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness Any abnormalities in liver, kidney or hematologic function laboratory tests immediately prior to randomization Sensitivity to any of the study medications, any of the ingredients or excipients of these medications, or benzyl alcohol Pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>